| 2026-08-06 | Presentation | Corporate Presentation – August 2026 |
| 2026-08-04 | Press release | Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-07-28 | Press release | Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 |
| 2026-07-14 | Press release | 07.14.26 Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event – Expands pipeline with SND |
| 2026-06-11 | Press release | 06.11.26 Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EH |
| 2026-06-11 | Press release | 06.11.26 Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine |
| 2026-06-04 | Document | 0001193125-26-256557.pdf |
| 2026-06-04 | Press release | 06.04.26 Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes NEW YORK, June 04, 2026 (GLOBE |
| 2026-06-02 | Press release | 06.02.26 Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Tra |
| 2026-06-01 | Press release | 06.01.26 Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 NEW YORK, J |
| 2026-05-20 | Press release | 05.20.26 Syndax Announces Participation in Upcoming Investor Conferences NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Synd |
| 2026-05-12 | Press release | 05.12.26 Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhib |
| 2026-04-30 | Document | 0001193125-26-197859.pdf |
| Document | Syndax Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-04-30 | Presentation | First Quarter 2026 Conference Call Presentation |
| Press release | 04.24.26 Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 |
| 2026-02-26 | Presentation | Fourth Quarter 2025 Conference Call Presentation |
| Press release | Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-02-23 | Press release | 02.23.26 Syndax Announces Participation in March Investor Conferences NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax |
| Press release | 02.19.26 Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on |
| 2026-02-05 | Press release | 02.05.26 Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit NEW YORK, Feb. 05, 2026 |
| 2026-01-12 | Presentation | View Presentation |
| 2026-01-12 | Press release | 01.12.26 Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morg |
| 2026-01-07 | Press release | 01.07.26 Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Re |
| 2026-01-05 | Press release | 01.05.26 Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference NEW YORK , Jan. 05, 2026 (GL |
| 2025-12-12 | Press release | 12.12.25 Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025 NEW YORK , Dec. 12, 2025 (GLOBE NEWSWIRE) -- |
| 2025-12-08 | Investor meeting | Syndax ASH 2025 Investor Event Presentation |
| 2025-12-08 | Press release | 12.08.25 Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations |
| 2025-12-01 | Press release | 12.01.25 Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference NEW YORK , Dec. 01, 2025 (GLOBE |
| 2025-11-03 | Presentation | Third Quarter 2025 Conference Call Presentation |
| Press release | 11.03.25 Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update – $45.9 million in total reven |
| 2025-11-03 | Press release | 11.03.25 Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 NEW YORK , Nov. 03, 2025 (GLOBE |
| 2025-11-03 | Press release | 11.03.25 Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentatio |
| 2025-10-30 | Press release | 10.30.25 Syndax Announces Participation in November Investor Conferences NEW YORK , Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sy |
| Press release | 10.27.25 Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 202 |
| 2025-10-24 | Presentation | Revuforj® (revumenib) FDA Approval in R/R NPM1 Mutated AML Presentation |
| 2025-10-24 | Press release | 10.24.25 Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refract |
| 2025-08-26 | Press release | 08.26.25 Syndax Announces Participation in September Investor Conferences NEW YORK , Aug. 26, 2025 (GLOBE NEWSWIRE) -- S |
| 2025-08-04 | Presentation | Second Quarter 2025 Conference Call Presentation |
| Press release | 08.04.25 Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update – $28.6 million of Revuforj ® |